Project description:Longitudinal single cell RNA-expression analysis of tumor cells along the metastatic cascade. AKTP MTOs were implanted in the caecum and left to metastasize into the liver. Mice with different metastatic burden were collected and GFP+ CD45- cells were sorted in 96-well smart-seq plates. Tumor cells were collected at four stages (Primary tumors, micrometastases, small metastases and big metastases) and each Smart-seq2 plate contained cells from all conditions to avoid batch effects. Primary tumor samples were matched with micro, small or big metastases samples.
Project description:Using liver metastases from 4 colorectal cancer patients (CRC-LM), we explored one receptor: EGFR whose signaling triggers cell proliferation and is exacerbated in many tumors.
Project description:Longitudinal single cell RNA-expression analysis of tumor cells along metastatic relapse. AKP mouse tumor organoids (MTOs) were implanted in the caecum and left to metastasize into the liver. Livers were collected at different timepoints post-injection and GFP+ CD45- cells were sorted in 96-well smart-seq plates. Tumor cells were collected from liver with colorectal cancer (CRC) micrometastatic stage disease.
Project description:We investigated spatiotemporal molecular patterns related to AD pathophsiology using spatially resolved transcriptome of the AD mouse model. The late change of gray matters of AD was commonly related to neuroinflammation, while the early change in the white matter of AD represented neuronal projection and ensheathment of axons before the amyloid plaques accumulation. Disease-associated microglia and astrocyte signatures were spatially differently enriched. Our results provide a key spatiotemporally heterogeneous molecular change particularly related to inflammation in AD.
Project description:The purpose of this study is to identify lncRNAs involved in the pathology of colorectal cancer (CRC) liver metastasis and investigate their underlying mechanisms. A total of 439 miRNAs were identified to be differentially expressed between 7 primary CRC tissues with liver metastases and 8 CRC tissues without liver metastases from 15 patients by Arraystar lncRNA microarrays
Project description:Colorectal cancer (CRC) is the third most common and second most deadly cancer worldwide. Treatments for metastatic CRC (mCRC) are still largely based on toxic chemotherapy regimens, but important insights into tumor biology enabled the development of targeted cancer therapies. Here, we describe a proteogenomic analysis of CRC liver metastases (metastatic CRC, mCRC), an ideal setting to analyze therapeutic resistance which occurs in a short time frame. We selected liver metastases from two CRC patients on both of which we performed deep proteome profiling and WES and RNAseq-directed database searches, identifying 10 predicted muttaions, one of which was KRAS G12V. finding we generated targeted parallel reaction monitoring (PRM) assays using stable isotope labelled standard (SIS) peptides to quantify the actual concentration (fmol per µg of total protein) of the mutated and canonical (wildtype) protein variants for 8 different mutations. We demonstrate on a total of 8 tumor and 6 paired healthy tissue samples (7 and 6 out of these KRASG12V) that PRM allows quantifying the actual mutation rate on the protein level from as little 10 µg of total protein starting amount and within a single 1 hour nano-LC-MS/MS run.
Project description:This study was conducted in order to identify biomarkers for a prognostic gene expression signature for metastases in early stage CRC.